Canada Markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.62+0.03 (+0.40%)
At close: 04:00PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Amryt Reports Record Q2 2022 Results

    Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four

  • GlobeNewswire

    Amryt to Report Q2 2022 Results on August 4, 2022

    DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2022 will be released on Thursday, August 4, 2022 at 0700 ET/1200 BST. Amryt will host a conference call and webcast for analysts and investors on August 4, 2022 at 0830 ET/1330 BST. Webcast Player URL: https://e

  • GlobeNewswire

    Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome

    Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mycapssa® for the treatment of carcinoid syndrome. Carci